S Chandrakala, Manoj Toshniwal, Mitesh Halvawala, Namita Padwal, Neeraj Sidharthan, Pankaj Malhotra, B Prashantha, Riya Ballikar, Sandip Shah, Shashikant Apte, T Kasi Viswanathan, Vijay Ramanan, Akhilesh Sharma, Dattatray Pawar, Roshan Pawar, Vinayaka Shahavi
Romiplostim is a Food and Drug Administration (FDA)-approved therapy for immune thrombocytopenia (ITP). Biosimilar is a biological product that has no clinical meaningful difference from an existing FDA-approved reference product. It has a potential of lowering health-care-related cost. Biosimilar of romiplostim can be made available to patients with ITP at a low cost and can be beneficial in providing the best therapy. Thus, the efficacy and safety of biosimilar romiplostim (ENZ110) was compared with innovator romiplostim (Nplate) with respect to platelet response in patients with chronic ITP...
July 2023: Indian Journal of Hematology & Blood Transfusion